BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2025; 15(4): 105732
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.105732
Middle- and long-term survival of patients with heart transplant in Mexico from 1988 to 2023: A group experience
Guillermo Careaga-Reyna, Hugo Jesus Zetina-Tun
Guillermo Careaga-Reyna, Medical Attention Unit, Instituto Mexicano del Seguro Social, Mexico City 06600, Ciudad de México, Mexico
Hugo Jesus Zetina-Tun, Heart Transplant Clinic, Unidad Médica de Alta Especialidad General Hospital “Dr. Gaudencio González Garza” of the Centro Medico Nacional “La Raza”, Instituto Mexicano del Seguro Social, Mexico City 02990, Ciudad de México, Mexico
Co-first authors: Guillermo Careaga-Reyna and Hugo Jesus Zetina-Tun.
Author contributions: Careaga-Reyna G designed and conducted the study and wrote the paper; Zetina-Tun HJ provided the information and contributed to the analysis; Careaga-Reyna G and Zetina-Tun HJ contributed equally as co-first authors.
Institutional review board statement: This study was approved by Bioethics Board (August 18, 2023).
Informed consent statement: The analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guillermo Careaga-Reyna, Chief Physician, Medical Attention Unit, Instituto Mexicano del Seguro Social, Avenue Paseo de la Reforma 476, Mexico City 06600, Ciudad de México, Mexico. gcareaga3@gmail.com
Received: February 6, 2025
Revised: February 27, 2025
Accepted: April 15, 2025
Published online: December 18, 2025
Processing time: 286 Days and 13.7 Hours
Abstract
BACKGROUND

Heart transplantation is the last and best option for end-stage heart failure management. Early mortality rates have significantly decreased, enabling patients to survive longer with fewer complications, a trend observed even in our setting. The primary shared challenge has centered on achieving surgical success and immediate survival. The question arises about the medium- and long-term survival of patients with heart transplant in Mexico.

AIM

To present the results of the medium and long-term follow-up of heart transplant patients.

METHODS

This was a retrospective study of a single medical unit, and we selected patients who received heart transplants from July 21, 1988 to September 30, 2023. Selection criteria encompassed age, sex, and primary indication for heart transplantation across all groups. Patients with incomplete information or who died within 30 postoperative days were excluded. Data of primary pathology, ischemic, extracorporeal circulation, aortic cross-clamping times, length of ventilatory support, stay in postoperative therapy, hospitalization, and functional class were analyzed.

RESULTS

The causes of morbidity, mortality, and percentage of survival at 1, 5, and 10 years were examined. Overall, 257 heart transplants were performed during the study period. Of the total cases, 22 with incomplete data and 47 who died within 30 postoperative days were excluded for the middle- and long-term survival analyses. Of the remaining 188 patients, heart transplantation was performed (males: 146, females: 42). The average age of the participants was 44.43 ± 14.48 years. The primary indications included ischemic cardiomyopathy (42.55%) and dilated cardiomyopathy (39.36%). The mean durations of mechanical ventilator support, intensive care stay, and hospital stay were 57.55 ± 103.50 hours, 9.96 ± 8.59 days, and 19.49 ± 18.23 days, respectively. One-, five-, and ten-year survival rates were 90.7%, 71.3%, and 60.3%, respectively. Of the patients, 94% and 6% were in functional classes I and II, respectively. Infection and neurological hemorrhagic or ischemic stroke (26%) were the main causes of mortality in the first year. Subsequently, chronic rejection manifesting as graft vasculopathy increased in frequency (30%).

CONCLUSION

In our setting, heart transplantation yields medium- and long-term survival and quality of life outcomes comparable to those achieved by other international centers.

Keywords: Heart transplantation; Graft vasculopathy; Rejection reaction; Immunosuppression; Survival

Core Tip: In Mexico, ensuring surgical success and immediate survival in heart transplantation recipients constitute a significant challenge. The dilemma arises regarding the medium- and long-term survival of patients receiving heart transplant. The results of this review revealed 1- and 5-year survival rates of 90% and 71%, respectively. Notably, globally, current selection criteria for heart transplant candidates now include patients who were previously deemed ineligible. Adapting short- and long-term treatment and management protocols will be necessary.